Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases
Department of Neurology
Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Caspase 1; Humans; Inflammation; Magnetic Resonance Imaging; Multiple Sclerosis; Neurodegenerative Diseases; Neuroprotective Agents; Parkinson Disease; Stroke
Nervous System Diseases | Neurology
Multiple sclerosis is considered a disease of myelin destruction; Parkinson's disease (PD), one of dopaminergic neuron depletion; ALS, a disease of motor neuron death; and Alzheimer's, a disease of plaques and tangles. Although these disorders differ in important ways, they also have common pathogenic features, including inflammation, genetic mutations, inappropriate protein aggregates (e.g., Lewy bodies, amyloid plaques), and biochemical defects leading to apoptosis, such as oxidative stress and mitochondrial dysfunction. In most disorders, it remains uncertain whether inflammation and protein aggregation are neurotoxic or neuroprotective. Elucidating the mechanisms that orchestrate neuronal diseases should facilitate development of neuroprotective and neurorestorative strategies.
J Neuroimmunol. 2006 Jul;176(1-2):198-215.
Journal of neuroimmunology
Dhib-Jalbut S, Arnold DL, Cleveland DW, Fisher M, Friedlander RM, Mouradian MM, Przedborski S, Trapp BD, Wyss-Coray T, Yong VW. (2006). Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases. Neurology Publications. Retrieved from https://escholarship.umassmed.edu/neuro_pp/168